Literature DB >> 10779135

Expressions of human sodium iodide symporter mRNA in primary and metastatic papillary thyroid carcinomas.

H J Park1, J Y Kim, K Y Park, G Gong, S J Hong, I M Ahn.   

Abstract

The sodium iodide symporter (NIS) is a plasma membrane protein that is responsible for iodide transport into thyroid cells. To understand the regulation and expression of human NIS (hNIS) in papillary thyroid carcinomas, we evaluated the expression levels of hNIS mRNA in primary and lymph node metastatic papillary carcinoma tissues. The correlation of mRNA levels between hNIS and thyroid-specific genes, thyrotropin (TSH) receptor, and thyroglobulin (Tg), were also investigated. Twenty-three cases of papillary carcinoma and 7 pairs of primary and lymph node metastastic tissues were included in this study. We measured the expression levels of hNIS, TSH receptor, and Tg mRNAs by semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) and RNase protection assay (RPA). The levels of hNIS mRNA in lymph node metastatic tissues were evaluated by RT-PCR. By semiquantitative RT-PCR, 87% of papillary carcinoma (20/23) expressed hNIS mRNA, but the degrees of expression were variable and were lower than those of normal thyroid tissues. The decreased expression of hNIS mRNA in papillary carcinoma compared to normal thyroid tissue was also noticed by RPA. All 23 papillary carcinomas in this study showed the expression of TSH receptor and Tg mRNAs. The levels of TSH receptor mRNA were again lower in papillary thyroid carcinomas than in normal controls. The level of hNIS mRNA was correlated with the levels of TSH receptor (r = 0.449, p < 0.05), but not with Tg mRNA. In addition, significant correlation of mRNA level was observed between TSH receptor and Tg (r = 0.706, p < 0.01). Two of six lymph node metastatic tissues did not show hNIS mRNA even with significant hNIS expressions in papillary carcinoma tissues in thyroid. The levels of hNIS expression of the remaining four lymph node metastatic tissues were lower than those of corresponding primary tissues. Interestingly, one case showed no hNIS expression in primary tissue, but significant hNIS expression in lymph node metastatic tissue. No correlation was found in hNIS mRNA expression between primary and lymph node metastatic tissues. Our results suggest that the measurements of hNIS mRNA level in primary tissues may not predict the therapeutic response to radioactive iodine.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10779135     DOI: 10.1089/thy.2000.10.211

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  11 in total

1.  Methylation of sodium iodide symporter promoter correlated with aggressiveness and metastasis in papillary thyroid carcinoma: a meta-analysis.

Authors:  Jun-Yu Zhao; Huan-Jun Wang; Hai-Peng Wang; Jin-Ming Yao; Xiao-Yun Wu; Hong-Xia Shang; Rui Zhang; Huan-Gao Zhu; Jian-Jun Dong; Lin Liao
Journal:  Int J Clin Exp Med       Date:  2015-07-15

Review 2.  The biology of the sodium iodide symporter and its potential for targeted gene delivery.

Authors:  Mohan Hingorani; Christine Spitzweg; Georges Vassaux; Kate Newbold; Alan Melcher; Hardev Pandha; Richard Vile; Kevin Harrington
Journal:  Curr Cancer Drug Targets       Date:  2010-03       Impact factor: 3.428

3.  Relationship of sodium/iodide symporter expression with I131 whole body scan uptake between primary and metastatic lymph node papillary thyroid carcinomas.

Authors:  S J Lee; K-C Choi; J P Han; Y-E Park; M G Choi
Journal:  J Endocrinol Invest       Date:  2007-01       Impact factor: 4.256

4.  A novel mechanism of sodium iodide symporter repression in differentiated thyroid cancer.

Authors:  Vicki E Smith; Martin L Read; Andrew S Turnell; Rachel J Watkins; John C Watkinson; Greg D Lewy; Jim C W Fong; Sally R James; Margaret C Eggo; Kristien Boelaert; Jayne A Franklyn; Christopher J McCabe
Journal:  J Cell Sci       Date:  2009-08-25       Impact factor: 5.285

5.  Distribution of Na+/I- symporter in thyroid cancers in an iodine-deficient population: an immunohistochemical study.

Authors:  Anjali Mishra; Lily Pal; Saroj Kanta Mishra
Journal:  World J Surg       Date:  2007-09       Impact factor: 3.352

6.  Clinical significance of discordant findings between pre-therapy (123)I and post-therapy (131)I whole body scan in patients with thyroid cancer.

Authors:  Paco E Bravo; Behnaz Goudarzi; Uzma Rana; Paulo Togni Filho; Raymond Castillo; Christopher Rababy; Marjorie Ewertz; Harvey A Ziessman; David S Cooper; Paul W Ladenson; Richard L Wahl
Journal:  Int J Clin Exp Med       Date:  2013-05-22

7.  Evidence for transcriptional and posttranscriptional alterations of the sodium/iodide symporter expression in hypofunctioning benign and malignant thyroid tumors.

Authors:  Séverine Trouttet-Masson; Samia Selmi-Ruby; Françoise Bernier-Valentin; Valérie Porra; Nicole Berger-Dutrieux; Myriam Decaussin; Jean-Louis Peix; Agnès Perrin; Claire Bournaud; Jacques Orgiazzi; Françoise Borson-Chazot; Brigitte Franc; Bernard Rousset
Journal:  Am J Pathol       Date:  2004-07       Impact factor: 4.307

8.  Induction of sodium/iodide symporter (NIS) expression and radioiodine uptake in non-thyroid cancer cells.

Authors:  Zhi Liu; Mingzhao Xing
Journal:  PLoS One       Date:  2012-02-16       Impact factor: 3.240

9.  The Thyroid Na+/I- Symporter: Molecular Characterization and Genomic Regulation.

Authors:  Hani Alotaibi; Merve Tuzlakoğlu-Öztürk; Uygar Halis Tazebay
Journal:  Mol Imaging Radionucl Ther       Date:  2017-02-09

10.  NIS expression in thyroid tumors, relation with prognosis clinicopathological and molecular features.

Authors:  Catarina Tavares; Maria João Coelho; Catarina Eloy; Miguel Melo; Adriana Gaspar da Rocha; Ana Pestana; Rui Batista; Luciana Bueno Ferreira; Elisabete Rios; Samia Selmi-Ruby; Bruno Cavadas; Luísa Pereira; Manuel Sobrinho Simões; Paula Soares
Journal:  Endocr Connect       Date:  2018-01       Impact factor: 3.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.